China (Mainland)
LIGANDROL(LGD-4033) CAS NO.1165910-22-4
- FOB Price: USD: 1.00-1.00 /Kilogram Get Latest Price
- Min.Order: 10 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,MoneyGram
- Available Specifications:
98%(1-100)Kilogram
- Product Details
Keywords
- SAMRS
- Product Specification : 98%
- Sample Requirement : Free Sample
Quick Details
- ProName: LIGANDROL(LGD-4033)
- CasNo: 1165910-22-4
- Molecular Formula: C14H12F6N2O
- Appearance: WHITE POWER
- Application: lose weight Increasing bone mineral d...
- DeliveryTime: immediately
- PackAge: 5kg/bag,10kg/bag or as demand
- Port: main China port
- ProductionCapacity: 500 Kilogram/Month
- Purity: >98%
- Storage: contact us
- LimitNum: 10 Kilogram
Superiority
excellent promotion
Details
Product Introduction
What is LIGANDROL(LGD-4033)
LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
How it works
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers.
Dosages and Suggestion
Recommended maximum dose LIGANDROL the safety and tolerability up to doses of 22 mg -25mg . It has a half-life of 24 hours a day.
SARMS We offer
|
AICAR |
2627-69-2 |
acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
|
MK2866 |
841205-47-8 |
medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
|
MK-677 |
15972-10-0 |
A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
|
LGD-4033 |
1165910-22-4 |
pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
|
GW1516 |
317318-70-0 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
|
Andarine(S4) |
401900-40-0 |
partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
|
SR9009 |
1379686-30-2 |
under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
|
SR9011 |
1379686-30-2 |
For obesity, diabetes, dyslipidemia and cardiovascular disease |
|
RAD140 |
1182367-47-0 |
New generation for gaining mass and cutting edges |
|
YK11 |
366508-78-3 431579-34-9 |
a SARM and myostatin inhibitor in one |
|
GHRP-2 |
158861-67-7 |
Growth Hormone Releasing Peptide-2 |
|
GHRP-6 |
87616-84-0 |
Growth Hormone Releasing Peptide-6 |
|
TB500 |
107761-42-2 |
Thymosin beta 4 |
|
SM130,686 |
/ |
/ |